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Background: In the present study, we show that the combination of doxorubicin with the cyclin-dependent kinase
inhibitor P276-00 was synergistic at suboptimal doses in the non-small cell lung carcinoma (NSCLC) cell lines and
induces extensive apoptosis than either drug alone in H-460 human NSCLC cells.
Methods: Synergistic effects of P276-00 and doxorubicin on growth inhibition was studied using the Propidium
Iodide (PI) assay. The doses showing the best synergistic effect was determined and these doses were used for
further mechanistic studies such as western blotting, cell cycle analysis and RT-PCR. The in vivo efficacy of the
combination was evaluated using the H-460 xenograft model.
Results: The combination of 100 nM doxorubicin followed by 1200 nM P276-00 showed synergistic effect in the
p53-positive and p53-mutated cell lines H-460 and H23 respectively as compared to the p53-null cell line H1299.
Abrogation of doxorubicin-induced G2/M arrest and induction of apoptosis was observed in the combination
treatment. This was associated with induction of tumor suppressor protein p53 and reduction of anti-apoptotic
protein Bcl-2. Furthermore, doxorubicin alone greatly induced COX-2, a NF-κB target and Cdk-1, a target of P276-00,
which was downregulated by P276-00 in the combination. Doxorubicin when combined with P276-00 in a
sequence-specific manner significantly inhibited tumor growth, compared with either doxorubicin or P276-00 alone
in H-460 xenograft model.
Conclusion: These findings suggest that this combination may increase the therapeutic index over doxorubicin
alone and reduce systemic toxicity of doxorubicin most likely via an inhibition of doxorubicin-induced
chemoresistance involving NF-κB signaling and inhibition of Cdk-1 which is involved in cell cycle progression.
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Lung cancer affects more than 1.2 million patients a year.
The prognosis of lung cancer is very poor and long-term
survival is obtained in only 5-10% of the patients. Non-
small cell lung cancer (NSCLC) constitutes approximately
85% of all lung cancers and is the leading cause of tumor-
related death worldwide highlighting the need for more* Correspondence: kalpana.joshi@piramal.com
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reproduction in any medium, provided the oreffective treatment strategies [1,2]. NSCLC are inherently
resistant and are generally not responsive to initial chemo-
therapy [3].
Treatment of advanced NSCLC with anthracyclines,
exemplified by doxorubicin, provides an overall re-
sponse rate of only 30–50%. Unfortunately, its acute
and cumulative dose-related toxicity poses a major
problem in therapeutic outcomes. In addition to tox-
icity, the development of inducible drug resistance is a
paramount problem in which patient fails to respond to
cancer drugs.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rently under consideration for lung cancer, as the clinical
use of cytotoxic drugs is limited due to intrinsic or
acquired resistance and toxicity. A better understanding
of the molecular mechanisms of cytotoxic drug action
has shed light on the treatment of lung cancer, and novel
agents that target specific intracellular pathways related
to the distinctive properties of cancer cells continue to
be developed [4]. Most DNA-damaging agents, including
doxorubicin, trigger cell death via activation of p53 [5].
The apoptotic role of p53 likely resides in its ability to
disrupt the balance between antiapoptotic proteins (such
as Bcl-XL, Bcl-2, and Mcl-1) and pro-apoptotic proteins
(such as Bax and Bak) [6]. Mee et al. (2008) have shown
that p53 is upstream of NF-κB-mediated pathways of
doxorubicin resistance and p53 is required for NF-κB
mediated resistance to doxorubicin in NSCLC.
Since dysfunctions in the regulation of the cell cycle
were found in almost all human cancers including
NSCLC, agents targeting proteins involved in the regula-
tion of cell cycle progression were developed [7]. Disrup-
tion of the Rb pathway is a frequent event in NSCLC
and plays an important role in tumorigenesis of NSCLCs
[8]. It has been hypothesized that the aberrant expres-
sion of cyclin D1 has strong oncogenic activity inde-
pendently of pRb and p16, and may override the
suppressive effects of pRb and p16. Other groups have
also shown that the deregulation of cyclin D1 expression
is an important characteristic of this disease [9]. These
data further strengthen the argument that cyclin D1 might
be an effective lung cancer therapeutic target.
P276-00 is a novel small molecule inhibitor of cyclin-
dependent kinases (Cdks) and has demonstrated syner-
gism with different chemotherapeutic agents and is in
Phase I/II clinical trials in combination with such
agents/radiation for various cancers [10]. In this study,
we investigated the effect of P276-00, doxorubicin and
their combination in three NSCLC cell lines differing in
their p53 status and their in vivo antitumor efficacy
against a human NSCLC (H-460) xenograft.
Methods
Cell culture and reagents
Human NSCLC cell lines H-460 (p53-positive), H1299
(p53-null) and H23 (p53-mutant) were obtained from
ATCC (Rockville, MD, USA) and cultured in RPMI-1640
medium containing 10% fetal bovine serum (FBS)
(Hyclone, UT, USA), 2 mmol/L L-glutamine (Gibco,
Grand Island, NY, USA), 100 U/mL penicillin and
100 mg/mL streptomycin (Gibco). Cells were maintained
at 37°C in a humidified atmosphere containing 5% CO2.
P276-00 was synthesized at Piramal Healthcare Limited,
Mumbai, India and doxorubicin was purchased from
Sigma. Both drugs were dissolved in dimethyl sulfoxide(DMSO) at a concentration of 10 mmol/L (10 mM) and
stored at −20°C until use; diluted in culture medium
RPMI-1640 immediately before use and used within 4 h.
All reagents were purchased from Sigma (St. Louis, MO,
USA) unless stated otherwise.
In vitro cytotoxicity assay
Cells were plated in 96-well plates and allowed to attach
overnight. Each concentration of doxorubicin and P276-
00 was represented by 3 wells per experiment and each
experiment was repeated three times. Treated cells were
maintained at 37°C in 5% CO2 for times indicated in the
legends to the figures. A modified propidium iodide (PI)
assay was used to assess the effect of the compounds on
the growth of the human tumor cell lines [11]. IC50
values were determined by plotting compound concen-
tration versus cell viability. The combination index (CI)
was calculated by the Chou-Talalay equation, which
takes into account both the potency and the shape of
the dose-effect curve taking advantage of the Compusyn
software (ComboSyn, Inc. NY, USA). The combination
index is used for the quantification of synergism or an-
tagonism for two drugs where CI< 1, =1, and >1 indicate
synergism, additive effect, and antagonism, respectively.
Analysis of cell cycle distribution by flow cytometry
H-460 cells were seeded in T-25 tissue culture flasks at a
density of 1.0 × 106/mL and incubated overnight at 37°C.
Next day the cells were treated with compounds. At the
end of treatment period the cells were harvested and pro-
cessed for flow cytometry as described previously [11].
Annexin V staining
Annexin V staining was performed as described by the
manufacturer (BD Biosciences). Briefly, 1 × 105 cells
were washed twice in PBS and resuspended in binding
buffer (10 mM HEPES, NaOH (pH 7.4), 140 mM NaCl,
2.5 mM CaCl2) at a concentration of 1 × 10
6 cells/ml.
5 μl of FITC-Annexin V (BD Biosciences) and 10 μl of
PI (500 μg/ml in 38 mM sodium citrate) were added,
and the cells incubated for 15 min in the dark at room
temperature. A total of 400 μl of binding buffer was then
added and the cells analyzed by flow cytometry.
Preparation and analysis of cell lysates by
immunoblotting
Cells were seeded, treated with or without P276-00 or
doxorubicin or their combination and were harvested at
desired time points and western blotting was carried out
as previously described [12]. Antibodies used in this
study were: Bcl-2, Bax, p53, Cdk-1, cyclin D1 (Santacruz
Biotechnology, CA, USA), Cox-2 (Cell signaling techno-
logy, USA), anti-rabbit–HRP and anti-mouse-HRP se-
condary antibodies (Santacruz Biotechnology, CA, USA).
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H-460 cells were seeded at a density of 750–1000 cells
per 35 mm tissue culture grade plate and incubated
overnight at 37°C for the cells to attach. The cells were
treated with the cytotoxic drug doxorubicin for 24 h fol-
lowed by removal of medium and addition of fresh
medium containing P276-00 for 96 h. At the end of the
treatment, the medium was replaced by fresh complete
medium and incubated for 7–14 days for colony forma-
tion. When visible colonies appeared on the plate the
medium was removed and colonies were fixed with
methanol: acetic acid mixture in the ratio of 2:1 for
5 min. The plates were washed with water and the fix-
ation procedure was repeated. The plates were dried and
the colonies were stained with 0.1% crystal violet stain
for 3–5 min. The plates were rinsed carefully with water
and dried and the colonies counted.
Tumor xenograft model
Approximately 5 × 106 H-460 cells were subcutaneously
injected into severe combined immunodeficient (SCID)
mice in 0.2 ml volume on the right flank and observed
daily for tumor appearance. When the tumors attained a
diameter of ~50 mm3, they were randomized into four
groups: Group I, control vehicle; Group II, doxorubicin
2 mpk ip. once a week for 2 weeks; Group III, P276-00
20 mpk ip. every day for 5 days a week for 2 weeks;
Group IV, combination of doxorubicin and P276-00,
doxorubicin was followed by P276-00 after an interval of
6 h, followed everyday with P276-00 for a total of five
days which comprised of one cycle. The treatment com-
prised of total of two cycles. Body weight was recorded
everyday. Tumor measurements i.e. the length and width
of the tumors were measured using the vernier caliper.
Tumor weight (mg) was estimated according to the for-
mula for a prolate ellipsoid: {Length (mm) x [width
(mm)2] x 0.5} assuming specific gravity to be one and π
to be three. Tumor growth in compound treated animals
is calculated as T/C (Treated/Control) x 100% and
growth inhibition percent (GI %) was [100-T/C%]. Ani-
mals were maintained and experiments were carried out
as per the institutional animal ethical committee in com-
pliance with the guidelines of the Committee for the
Purpose of Control and Supervision on Experiments on
Animals (CPCSEA), India.
Statistical analysis
Statistical comparison was made using GraphPad Prism
software (version 5.0) in which one-way analysis of variance
and Tukey’s multiple comparison post tests were used to
determine significant differences between several treatment
groups. Student’s paired t-test was used when only two
groups were compared. Data are presented as mean ± S.E.
M. of at least three independent experiments with tripli-cate. Statistical significance was evaluated by calculating
P-values. Differences where P < 0.05 were considered statis-
tically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
Results
Effect of P276-00 and doxorubicin on cell proliferation
Three NSCLC cell lines H-460, H1299 and H23 were
treated with increasing concentrations (0.01-10 μM) of
P276-00 for 72 h and cell proliferation was assessed.
Treatment with P276-00 caused a dose-dependent de-
crease in the proliferation of all the three cell lines
(Figure 1A). Thus, P276-00 was an effective inhibitor of
NSCLC cancer cell growth as a single agent, and H-460
and H1299 were more sensitive than H23 as seen from
the IC50 values (Figure 1B). Doxorubicin was also effect-
ive as a single agent and H-460 was highly sensitive to
doxorubicin while H1299 and H23 were moderately sen-
sitive (Figure 1C and 1D).
P276-00 potentiates growth inhibition induced by
doxorubicin in various human NSCLC cell lines
The anthracycline antibiotic doxorubicin is commonly
used in lung cancer treatment regimens. However, in
contrast to its high activity in SCLC, doxorubicin is not
curative in NSCLC which represents 4/5 of all lung can-
cers [13]. To determine if P276-00 enhances the sensitiv-
ity of NSCLC cells to the growth inhibitory effect of
doxorubicin, combination studies were done. Cells were
either treated with P276-00 (IC50 concentration) or
doxorubicin or in combination with serial concentra-
tions of doxorubicin (0.01-10 μM) followed by P276-00
(IC50 concentration) for 72 h and cell viability was evalu-
ated. Combination treatment yielded significantly greater
growth inhibition in a dose-dependent manner than ei-
ther agent alone in all three cell lines (Figure 1E). The
combination index method developed by Chou [14] was
used to confirm and quantify the synergism observed
with doxorubicin and P276-00. The CI values of the
combination of IC50 of P276-00 with various concentra-
tion of doxorubicin were calculated using CompuSyn
software. The p53 positive H-460 and p53 mutant H-23
cell lines showed synergism with CI range of 0.63-0.94
and 0.86-0.9 respectively. The combination of doxorubi-
cin followed by P276-00 was not synergistic in the p53
null H1299 cell line. For all further studies, H-460 cell
line was selected, which possesses wild type p53 gene,
mutant KRAS and wild type EGFR [15].
Synergistic cytotoxicity of doxorubicin and P276-00
combination is due to increased apoptosis
We observed induction of apoptosis in H-460 cells trea-
ted with either doxorubicin or P276-00 or both
(Figure 2A, 2B and 2C). Relative to single agents, the
combination treatment induced more apoptosis as



































































































Figure 1 (See legend on next page.)
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Figure 1 (A & B) The effect of P276-00 and doxorubicin treatment on growth of three NSCLC cell lines. Cells were seeded in 96-well
plates and incubated overnight. P276-00 was added at the indicated concentrations and cells were further incubated for 48 h. Cell proliferation
was determined using PI assay. (C & D) The 50% inhibitory concentrations of P276-00 and doxorubicin in three different NSCLC cell lines.
(E) Effect of P276-00 and doxorubicin used singly or in combination on survival of H-460, H1299, H23 cell lines. The cells were treated as
described under Materials and method section. There was significantly higher growth inhibition of the cells treated with doxorubicin (24 h)
followed by P276-00 at IC50 concentration for 72 h compared to the cells treated with either agent alone.
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rubicin induced G2/M arrest, which was overcome by
subsequent P276-00 treatment. These results are con-
sistent with cell growth inhibition studies. The combin-
ation of 100 nM doxorubicin (24 h) followed by 1200
nM (IC50) of P276-00 for 72 h was found to be the most
synergistic and hence used for further mechanistic
studies.
NSCLC cells continue to undergo apoptosis in
combination treatment even after the drugs are removed
Recovery experiment
In this experiment, cells were first treated with either
doxorubicin (24 h) or P276-00 (96 h) or combination of
both. After the treatment, drugs were removed and cells
were further incubated in fresh medium without drug
treatment. As indicated in Figure 2E at the end of 120 h
P276-00 and doxorubicin showed 32 and 3% of apop-
tosis respectively, whereas combination showed in-
creased apoptosis of 55%. At this point one set of
samples viz. control, P276-00, doxorubicin and combin-
ation was analyzed for early induction of apoptosis using
Annexin V binding assay and the second set of same
samples was incubated with fresh medium and analyzed
by flow cytometry at 6, 18, 24 and 48 h time points. It
was observed that doxorubicin did not induce further
apoptosis, while the combination showed the greatest in-
crease in apoptosis of 57% by the end of 48 h indicating
that cells in the combination treatment continued to
undergo apoptosis.
One of the early changes during apoptosis is loss of
plasma membrane asymmetry that exposes phosphati-
dylserine on the cell surface. This process precedes loss
of plasma membrane integrity and can be detected by
Annexin V binding. Annexin V binding analysis after
the combination treatment confirmed that this treat-
ment effectively induced apoptosis leading to phospho-
serine externalization (Figure 3A). 34.3% cells stained by
both Annexin and PI had already undergone apoptosis
in the combination as compared to either drug alone
(~8%). Interestingly 50.2% of the population was
Annexin-V positive indicating that the cells had already
entered apoptosis when fresh medium was added and
hence these cells continued to undergo apoptosis and
did not recover. Therefore, in combination after medium
change, total 84.5% (50.2 + 34.2%) cells are either justentering apoptosis or in the early stages of apoptosis
verses ~40% for either drug alone (Table 1). Cytotoxicity
assay and flow cytometry were complemented with the
conventional clonogenic assay in H-460. It demonstrates
a significant synergistic effect between both the drugs
(Figure 3B), as seen from the number of colonies in the
combination as compared to drug alone.
Effect of combination of P276-00 and doxorubicin on cell
cycle related and antiapoptotic proteins
Next, we analyzed whether combination treatment could
inhibit the expression of cell cycle related proteins and
antiapoptotic proteins that are modulated by doxorubicin
and could be involved in chemoresistance (Figure 4A).
Cdk-1 levels that were upregulated by doxorubicin treat-
ment were inhibited when followed by P276-00 exposure.
Additionally p53 was significantly increased and Bcl-2 was
decreased after combination treatment but not with either
agent alone. There was no significant change in Bax levels
on treatment with either drug alone or with combination.
Earlier studies have indicated that NF-κB activation
plays an important role in inducible chemoresistance to
anthracycline drugs in many cancer cells [16]. COX-2
has been shown as a target gene for NF-κB and impli-
cated in lung cancer growth. Protein and gene expres-
sion studies indicated that P276-00 downregulated
protein levels of COX-2 which were upregulated after
doxorubicin treatment (Figure 4A). Gene expression
levels of both Cdk-1 and its cyclin partner cyclin B1 are
significantly downregulated at 24 h post P276-00 treat-
ment. However, moderate decrease in cyclin D1 and
Cdk4 levels was observed at 2 and 6 h post P276-00
treatment (Figure 4A). The densitometry plots of the
RT-PCR bands are shown in Additional file 1: Figure S1.
P276-00 potentiates anti-tumor effect of doxorubicin in
xenograft model of NSCLC
The effects of the combination on human NSCLC H-460
tumor xenograft was studied to determine if the synergy
observed in vitro between P276-00 and doxorubicin also
occurred in vivo. Treatment with either P276-00 (20 mpk
once daily) or doxorubicin (2 mpk once a week) was
initiated when tumors reached a size of ~50 mm3 in dia-
meter. P276-00 and doxorubicin alone caused significant
suppression of tumor growth, while the combination of








































































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 The effect of P276-00, doxorubicin and the combination of doxorubicin followed by P276-00 on cell proliferation, cell cycle
and on recovery of cells after the treatment. (A) Cells were treated with 200 nM doxorubicin for 24 h or 800 nM of P276-00 for 72 h or
combination of both. (B) Cells were treated with 100 nM doxorubicin for 24 h or 1200 nM P276-00 for 96 h or combination of both. (C) Percent
of cell population in different phases of cell cycle. (D) Percent of cell population in sub-G1 phase after treatment with either drug alone or
combination for 96 h and 120 h and (E) Recovery of cells after the drug treatment was studied at different timepoints i.e. 0 h, 6 h, 18 h, 24 h and
48 h. Cell cycle analysis using Flow cytometry shows the percentage apoptosis in drug alone and combination treatment in comparison to
untreated control.
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of 82% was seen at the end of the treatment period as com-
pared to P276-00 (64%) and doxorubicin (56%) (P ≤ 0.05)
(Figure 5B). No body weight loss was observed in both the
combination and single drug treated groups indicating that
the doses and schedule were well tolerated.Figure 3 (A) Annexin-V staining for detection of apoptosis and (B)
Clonogenic assay in H-460 cells after treatment with doxorubicin
alone (100 nM for 24 h) or P276-00 (1200 nM for 96 h) alone or
combination of doxorubicin (24 h) > P276-00 (96 h).Discussion
We evaluated the cytotoxic effects of either doxorubicin
or P276-00 or the combination of both the compounds
in three NSCLC cell lines viz. H-460 (p53-positive),
H1299 (p53-null) and H23 (p53-mutant). A sequential
drug treatment strategy was chosen based on previous
studies demonstrating sequence-specific synergistic
effects with administration of combination of chemo-
therapy (doxorubicin) and Cdk inhibitor P276-00 (data
not shown). The combination was synergistic in the p53
positive and p53 mutant cell line but not p53 null cell
line indicating that p53 may possibly have a role in the
synergistic interaction. Similar results have been ob-
served with combined treatment of doxorubicin and an-
other Cdk inhibitor roscovitine in human sarcoma cell
lines [17]. It has been shown earlier that doxorubicin
mediated cell cycle arrest can occur either at G0/G1 or
G2 check points and is thought to be mediated by the
multifunctional transcription factor p53 [18]. Doxoru-
bicin is more effective in p53 wild type cancers. Our
results were in line with this finding – the best syner-
gism between the two drugs was observed in H-460
(p53-positive) cell line and hence it was selected for all
further studies.
Cell cycle analysis demonstrated that doxorubicin
alone markedly increased the percentage of cells in the
G2/M phase. Same response was seen earlier by other
groups in another doxorubicin sensitive human lung car-
cinoma cell line DLKP-SQ [19]. It has been proposed
that the G1 checkpoint is disabled in majority of cancers
as a prerequisite for tumorigenesis. The G2 checkpoint,
however, appears to remain functional in the majority of
cancer cells. Many conventional cancer therapeutic
agents exert their effect by causing DNA damage and
thus retaining a functional G2 is believed to confer re-
sistance to many such therapeutic agents. To circumvent
this, attempts have been made to develop abrogators of
this arrest in the G2 phase. Doxorubicin is also known
to cause G2 arrest in several cell lines and the target for
the G2 checkpoint pathway is Cdk1 [20]. Combination
treatment was found to downregulate Cdk1 expression
levels which could account for abrogation of G2/M ar-
rest and induction of apoptosis.
The checkpoint inhibitor p16 is practically always
silenced in NSCLC due to methylation of its promoter
Table 1 Percentage of H-460 cells in late or early apoptosis at the end of treatment period either with doxorubicin or
P276-00 alone or in the combination of doxorubicin followed by P276-00
Treatment group Percentage of cells
Live cells Annexin +ve Annexin + PI PI +ve
Control 90.5 3 4 2.3
Doxorubicin ( 100 nM) 60 30.4 8.6 1
P276-00 (1200 nM) 53 38.5 8.2 0.3
Doxorubicin> P276-00 14.1 50.2 34.3 2
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by the cyclin D- cyclin-dependent kinase 4, 6 complex
releasing E2F with the onset of the S phase of the cell
cycle. Gain of the 11q13.1-11q14.1 region has been
shown to be present in > 50% of the lung cancer cell
lines. Cyclin D1 is located at this loci and the amplifica-
tion of this gene is an important event in tumorigenesis
[22]. P276-00 is a potent Cdk4 and Cdk1 inhibitor [10]Figure 4 RT-PCR and Western blot analysis in H-460 cells.
(A) Effect of combination of P276-00 and doxorubicin or either of
the drugs alone on the protein levels 1. Control, 2. P276-00, 3.
doxorubicin, 4. doxorubicin> P276-00. (B) mRNA analysis of cyclin
B1, Cdk-1, cyclin D1, Cdk-4 and Cox-2. Samples were obtained from
H-460 cells treated with 100 nM of doxorubicin and/or 1200 nM
P276-00 at various time points as indicated in the figure.and therefore, downregulation of Cdk4, Cdk1, cyclin D1
and cyclin B1 was observed by P276-00 alone and in
combination. This could be a potential factor in the
increased sensitivity of H-460 to the combination com-
pared to either drug alone.
Many anticancer agents increase Bax protein and/or
decrease Bcl-2 protein during the apoptotic process.
Similarly, doxorubicin and P276-00-induced apoptosis in
H-460 cells was accompanied by an elevation of the Bax
to Bcl-2 ratio due to the downregulation of Bcl-2. p53
induces cell cycle arrest or apoptosis in response to
DNA damage and regulates Bax and Bcl-2 protein ex-
pression [4]. In response to the combination treatment,
p53 levels were significantly upregulated, which could
have lead to modulation of Bax and Bcl-2 expression.
One of the targets currently being evaluated in the
treatment of lung cancer belongs to the cyclooxygenaseFigure 5 The combination treatment of doxorubicin with
P276-00 showed significant tumor growth inhibition in H-460
xenograft model. (A) Differences in the tumour weight (mg).
(B) Percent growth inhibition after treatment. Statistically significant
difference (P <0.05) of the combination treatment of doxorubicin
and P276-00 compared with the control was seen.
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in many malignancies including lung cancer [1]. Re-
cently, it was shown by O’Kane et al. 2010 [23] that
COX-2 specific inhibitors enhance the cytotoxic effect of
conventional drugs. Doxorubicin causes the activation of
NF-κB in cancer cells, which in turn inhibits apoptosis
induced by doxorubicin; cells with increased activity of
NF-κB are thus resistant to doxorubicin [24]. P276-00
when added after doxorubicin treatment significantly
inhibited COX-2 protein levels which were increased in
response to doxorubicin treatment. The synergy observed
in vitro was also seen in in vivo antitumor efficacy studies
at well-tolerated doses and schedules. Anticancer efficacy
was more pronounced in combination (P ≤ 0.05) as com-
pared to either drug alone.Conclusions
There are various novel therapeutic strategies under con-
sideration, as the clinical use of cytotoxic drugs is limited
due to intrinsic or acquired resistance and toxicity. Recent
efforts have focused on identifying novel combinations of
anticancer agents with non-overlapping mechanisms of ac-
tion to obtain enhanced anticancer efficacy and reduced
toxicity. Our results provide substantial evidence for the hy-
pothesis that Cdk inhibitor P276-00 enhances doxorubicin-
induced killing of NSCLC cells in vitro as well as in vivo
without any significant toxicity especially in p53 positive
tumors. This study will potentially provide new approaches
to combination anticancer therapy for p53 positive NSCLC.Additional file
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